CorMedix Inc.

NasdaqGM CRMD

CorMedix Inc. Shareholders' Equity for the quarter ending September 30, 2024

CorMedix Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

CorMedix Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 83.20 M, a 47.75% change year over year.
CorMedix Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 56.31 M, a -18.79% change year over year.
CorMedix Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 69.34 M, a 101.18% change year over year.
CorMedix Inc. Shareholders' Equity for the quarter ending September 30, 2020 was USD 34.47 M, a 20.07% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: CRMD

CorMedix Inc.

CEO	Mr. Joseph Todisco MBA
IPO Date	May 13, 2010
Location	United States
Headquarters	300 Connell Drive
Employees	82
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Medical Instruments Non-Alcoholic Beverages Personal Care

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Key trends

Past 5 years